vs
Side-by-side financial comparison of NATURES SUNSHINE PRODUCTS INC (NATR) and VARONIS SYSTEMS INC (VRNS). Click either name above to swap in a different company.
VARONIS SYSTEMS INC is the larger business by last-quarter revenue ($173.1M vs $123.8M, roughly 1.4× NATURES SUNSHINE PRODUCTS INC). On growth, VARONIS SYSTEMS INC posted the faster year-over-year revenue change (26.9% vs 4.7%). VARONIS SYSTEMS INC produced more free cash flow last quarter ($49.0M vs $7.6M). Over the past eight quarters, VARONIS SYSTEMS INC's revenue compounded faster (15.2% CAGR vs 5.6%).
Nature's Sunshine Products, Inc. also known as "NSP", is a manufacturer of dietary supplements, including herbs, vitamins, minerals, and personal care products. It is based in Lehi, Utah, with a manufacturing facility in Spanish Fork, Utah.
Varonis Systems, Inc. is a software company based in Miami, Florida with R&D offices in Herzliya, Israel. The company’s Data Security Platform analyzes data and data activity using the insights to identify data exposure risks stemming from access permissions and software-as-a-service (SaaS) app configurations, triggering automated remediation capabilities in response.
NATR vs VRNS — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $123.8M | $173.1M |
| Net Profit | $4.1M | — |
| Gross Margin | 72.5% | 76.0% |
| Operating Margin | 4.3% | — |
| Net Margin | 3.3% | — |
| Revenue YoY | 4.7% | 26.9% |
| Net Profit YoY | 1379.4% | — |
| EPS (diluted) | $0.23 | $115788061.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $173.1M | ||
| Q4 25 | $123.8M | $173.4M | ||
| Q3 25 | $128.3M | $161.6M | ||
| Q2 25 | $114.8M | $152.2M | ||
| Q1 25 | $113.2M | $136.4M | ||
| Q4 24 | $118.2M | $158.5M | ||
| Q3 24 | $114.6M | $148.1M | ||
| Q2 24 | $110.6M | $130.3M |
| Q1 26 | — | — | ||
| Q4 25 | $4.1M | $-27.8M | ||
| Q3 25 | $5.3M | $-29.9M | ||
| Q2 25 | $5.3M | $-35.8M | ||
| Q1 25 | $4.7M | $-35.8M | ||
| Q4 24 | $-321.0K | $-13.0M | ||
| Q3 24 | $4.3M | $-18.3M | ||
| Q2 24 | $1.3M | $-23.9M |
| Q1 26 | — | 76.0% | ||
| Q4 25 | 72.5% | 78.9% | ||
| Q3 25 | 73.3% | 78.2% | ||
| Q2 25 | 71.7% | 79.5% | ||
| Q1 25 | 72.1% | 78.7% | ||
| Q4 24 | 72.0% | 83.6% | ||
| Q3 24 | 71.3% | 83.8% | ||
| Q2 24 | 71.4% | 82.8% |
| Q1 26 | — | — | ||
| Q4 25 | 4.3% | -17.5% | ||
| Q3 25 | 7.0% | -22.2% | ||
| Q2 25 | 3.7% | -24.0% | ||
| Q1 25 | 5.4% | -32.1% | ||
| Q4 24 | 3.8% | -11.1% | ||
| Q3 24 | 4.6% | -16.0% | ||
| Q2 24 | 5.1% | -22.1% |
| Q1 26 | — | — | ||
| Q4 25 | 3.3% | -16.0% | ||
| Q3 25 | 4.2% | -18.5% | ||
| Q2 25 | 4.6% | -23.5% | ||
| Q1 25 | 4.2% | -26.2% | ||
| Q4 24 | -0.3% | -8.2% | ||
| Q3 24 | 3.8% | -12.4% | ||
| Q2 24 | 1.2% | -18.4% |
| Q1 26 | — | $115788061.00 | ||
| Q4 25 | $0.23 | $-0.23 | ||
| Q3 25 | $0.30 | $-0.26 | ||
| Q2 25 | $0.28 | $-0.32 | ||
| Q1 25 | $0.25 | $-0.32 | ||
| Q4 24 | $-0.02 | $-0.12 | ||
| Q3 24 | $0.23 | $-0.16 | ||
| Q2 24 | $0.07 | $-0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $93.9M | $179.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $161.6M | $453.5M |
| Total Assets | $261.1M | $1.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $179.3M | ||
| Q4 25 | $93.9M | $883.7M | ||
| Q3 25 | $95.6M | $671.3M | ||
| Q2 25 | $81.3M | $770.9M | ||
| Q1 25 | $86.5M | $567.6M | ||
| Q4 24 | $84.7M | $529.0M | ||
| Q3 24 | $78.7M | $844.8M | ||
| Q2 24 | $68.7M | $582.5M |
| Q1 26 | — | $453.5M | ||
| Q4 25 | $161.6M | $598.7M | ||
| Q3 25 | $166.7M | $604.8M | ||
| Q2 25 | $163.7M | $341.5M | ||
| Q1 25 | $167.1M | $367.7M | ||
| Q4 24 | $161.0M | $455.7M | ||
| Q3 24 | $162.6M | $428.6M | ||
| Q2 24 | $156.4M | $458.6M |
| Q1 26 | — | $1.6B | ||
| Q4 25 | $261.1M | $1.8B | ||
| Q3 25 | $264.8M | $1.7B | ||
| Q2 25 | $254.9M | $1.6B | ||
| Q1 25 | $252.7M | $1.6B | ||
| Q4 24 | $240.9M | $1.7B | ||
| Q3 24 | $245.3M | $1.5B | ||
| Q2 24 | $235.8M | $1.1B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $9.9M | $55.0M |
| Free Cash FlowOCF − Capex | $7.6M | $49.0M |
| FCF MarginFCF / Revenue | 6.1% | 28.3% |
| Capex IntensityCapex / Revenue | 1.9% | — |
| Cash ConversionOCF / Net Profit | 2.41× | — |
| TTM Free Cash FlowTrailing 4 quarters | $28.8M | $118.2M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $55.0M | ||
| Q4 25 | $9.9M | $24.7M | ||
| Q3 25 | $18.5M | $33.4M | ||
| Q2 25 | $4.3M | $21.3M | ||
| Q1 25 | $2.6M | $68.0M | ||
| Q4 24 | $12.2M | $24.3M | ||
| Q3 24 | $9.6M | $22.5M | ||
| Q2 24 | $1.3M | $11.7M |
| Q1 26 | — | $49.0M | ||
| Q4 25 | $7.6M | $20.7M | ||
| Q3 25 | $16.8M | $30.4M | ||
| Q2 25 | $3.0M | $18.0M | ||
| Q1 25 | $1.5M | $65.7M | ||
| Q4 24 | $10.0M | $19.9M | ||
| Q3 24 | $7.9M | $21.3M | ||
| Q2 24 | $-2.0M | $10.9M |
| Q1 26 | — | 28.3% | ||
| Q4 25 | 6.1% | 12.0% | ||
| Q3 25 | 13.1% | 18.8% | ||
| Q2 25 | 2.6% | 11.8% | ||
| Q1 25 | 1.3% | 48.1% | ||
| Q4 24 | 8.5% | 12.6% | ||
| Q3 24 | 6.9% | 14.4% | ||
| Q2 24 | -1.9% | 8.4% |
| Q1 26 | — | — | ||
| Q4 25 | 1.9% | 2.3% | ||
| Q3 25 | 1.3% | 1.8% | ||
| Q2 25 | 1.2% | 2.2% | ||
| Q1 25 | 1.0% | 1.7% | ||
| Q4 24 | 1.9% | 2.7% | ||
| Q3 24 | 1.5% | 0.8% | ||
| Q2 24 | 3.0% | 0.6% |
| Q1 26 | — | — | ||
| Q4 25 | 2.41× | — | ||
| Q3 25 | 3.46× | — | ||
| Q2 25 | 0.81× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.21× | — | ||
| Q2 24 | 0.97× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
VRNS
| SaaS | $161.1M | 93% |
| Term license subscriptions | $6.9M | 4% |
| Maintenance and services | $5.2M | 3% |
